Company Encyclopedia
View More
name
vTv Therap
VTVT.US
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd.
1.946 T
VTVT.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking273/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-54.87%E
    • Profit Margin-138058.82%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-98.30%E
    • Net Profit YoY-28.21%D
    • Total Assets YoY130.50%A
    • Net Assets YoY293.81%A
  • Cash ScoreE
    • Cash Flow Margin-0.07%D
    • OCF YoY-98.30%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio29.10%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Promising Outlook for vTv Therapeutics: Buy Rating Affirmed Amidst Advancements in Type 1 Diabetes Treatment

    H.C. Wainwright analyst Emily Bodnar has reaffirmed a Buy rating on vTv Therapeutics with a price target of $36.00, citing positive developments in the company's Phase 3 CATT1 trial for Type 1 diabetes treatment. All 23 trial sites are activated, with patient enrollment expected to finish by Q1 2026. Recent $80 million PIPE financing supports the trial's progress, and the FDA has lifted a clinical hold. Promising results from earlier studies and Breakthrough Therapy Designation further enhance the outlook for cadisegliatin as a potential treatment.

    Tip Ranks·
    US
    VTVT
    +5.84%
    Tip Ranks·
    US
    VTVT
    +5.84%

    vTv Therap | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    VTVT
    +5.84%
    LB filings·
    US
    VTVT
    +5.84%

    vTv Therap | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    VTVT
    +5.84%
    LB filings·
    US
    VTVT
    +5.84%

    vTv Therapeutics Q3 net loss widens to $8.7 mln

    vTv Therapeutics reported a Q3 net loss of $8.7 million, attributed to increased R&D expenses for cadisegliatin development. The company completed an $80 million private placement to support its Phase 3 CATT1 trial. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $35.50, representing a 31.7% upside from its recent closing price of $24.24.

    Reuters·
    US
    VTVT
    +5.84%
    Reuters·
    US
    VTVT
    +5.84%

    vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half ...

    GlobeNewswire·
    US
    VTVT
    +5.84%
    GlobeNewswire·
    US
    VTVT
    +5.84%
    © 2025 Longbridge｜Disclaimer